CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium
- Status
- RECRUITING
- Phase
- PHASE2
- Last update posted
- 09/04/2026
- Start
- 06/03/2026
- Sponsor
- University of Milano Bicocca
- Specialties
- orthopaedics
Conditions: Perioperative Delirium; Hip Fracture; Post-Operative Cognitive Decline in Older Adults
Brief summary
The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or attenuate cognitive decline in older adults who develop perioperative delirium during hospitalization for proximal hip fracture. Delirium is a frequent and severe complication in this population and is associated with cognitive and functional deterioration, institutionalization, and mortality. Participants will be randomly assigned (1:1) to receive citicoline 1000 mg/day for 6 months after discharge, or usual care. Cognitive and functional status will be evaluated at discharge and subsequently at 3 and 6 months follow-up visits.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.
